APOC3 · GalNAc, SC
Plozasiran (Redemplo, EU)
An approved siRNA therapeutic silencing APOC3, indicated for Familial chylomicronemia syndrome. This page lists what the siRNA Atlas corpus holds on Plozasiran and links to each primary document.
Identity
- Generic name
- Plozasiran
- Brand name
- Redemplo (EU)
- Molecular target
- APOC3
- Indication
- Familial chylomicronemia syndrome
- Delivery
- GalNAc, SC
- FDA application
- NDA 219947
- Regulatory coverage
- FDA and EMA
Source documents in the corpus (4)
- FDAFDA prescribing information (current label)
- FDAFDA review
- EMAEMA public assessment report (EPAR)
- EMAEMA product information (SmPC)
Every answer about Plozasiran is drawn from these documents and the indexed literature, and cites the passage it used. Tables inside them are preserved, so numeric dosing, exposure and toxicology values stay searchable.
Ask the corpus about Plozasiran
- →What is the approved dose and dosing interval of plozasiran (Redemplo (EU))?
- →Describe the clinical pharmacology and ADME of plozasiran.
- →What did the regulatory reviews conclude about the nonclinical safety of plozasiran?
- →Summarise the pivotal trial evidence for plozasiran.
- →How does plozasiran silence APOC3, and how long does the effect last?
Other approved siRNA therapeutics
Information here is drawn from public regulatory records for reference and research. It is not medical advice — verify any clinical or regulatory decision against the current label and assessment report linked above.